CD274 and non-small cell lung carcinoma: In the setting of non-EGFR mutant resected NSCLC and subsequent AC, one notable ongoing study has been IMpower010 which is similarly examining the efficacy and safety of drug, in this case the anti-PD-L1 monoclonal antibody atezolizumab, compared to best supportive care (BSC) following AC in resected NSCLC [37].